Knowledge Library

Biophysical and Structural Biology Methods Enable Fragment-Based Ligand Discovery

Powerful biophysical and structural biology tools enable the study of large numbers of fragments and are opening new possibilities in the treatment of various diseases. In this webinar, WuXi AppTec presents the results of a conventional and covalent fragment-based drug discovery screen, and our expert speaker discusses how orthogonal biophysical and structural methods enable the …Read More >

Resource Type: Webinar
Resource Topic: Fragment-Based Drug Discovery Hit Finding Hit-to-Lead Lead Optimization

VIEW

Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor

DNA-dependent protein kinase (DNA-PK) plays an important role in the overall survival and proliferation of cells, making this enzyme an intriguing target for the treatment of a variety of cancers.  In our latest publication, WuXi AppTec scientists contributed to the discovery and characterization of ZL-2201, a potent and highly selective small molecule DNA-PK inhibitor.  In …Read More >

Resource Type: Latest Science Publication
Resource Topic: Cell-based Assays Hit-to-Lead Lead Optimization Oncology Tumor Models

VIEW

OncoWuXi Express: Large-scale Cell Panel Screening Platform for Integrated Pharmacogenomics and Bioinformatics Research

Introduction: OncoWuXi Express will continue to keep you informed about updates to our on-line tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we showcase our large-scale cell panel screening platform for integrated pharmacogenomics and bioinformatics research. Cell viability assessment is a commonly used in …Read More >

Resource Type: Article Blog Case Study
Resource Topic: Cell-based Assays Hit-to-Lead Lead Optimization Oncology

VIEW

Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors

The KRAS G12D mutation subtype is present in over 40% of pancreatic ductal adenocarcinomas (PDAC), making this an important drug target.  WuXi AppTec scientists recently contributed to a research article in ACS Med. Chem. Letters describing the optimization of a series of potent and selective KRAS G12D inhibitors through a structure-based drug design approach.  The …Read More >

Resource Type: Latest Science Publication
Resource Topic: Hit-to-Lead Lead Optimization Oncology Small Molecules Structural Biology

VIEW

Dianthus Platform: Screening for Modulators of SIK3

Salt-inducible kinases (SIKs) have recently emerged as key regulators of oncogenesis, inflammation, and immune responses, making these enzymes an important drug target. The isoform SIK3 is a novel regulator of tumor-intrinsic resistance to cytotoxic T cell attack. To support the discovery of novel SIK3 modulators, WuXi AppTec offers an integrated platform of ready-to-go biophysical assays …Read More >

Resource Type: Brochure
Resource Topic: Autoimmune and Inflammatory Diseases Biophysical Assays Hit Finding Hit-to-Lead Immunology Metabolic Diseases Oncology

VIEW

Dianthus Platform: Screening for CRBN-DDB1 Proteolysis-Targeting Chimeras and Molecular Glues

Cereblon (CRBN) forms an E3 ligase complex together with DDB1, CUL4, and RBX1. CRBN functions as a substrate receptor of this complex for the recognition and binding of proteins targeted for ubiquitination and proteasomal degradation.  To support the discovery of CRBN-DDB1 proteolysis-targeting chimeras and molecular glues, WuXi AppTec offers an integrated platform of ready-to-go assays …Read More >

Resource Type: Brochure
Resource Topic: Biophysical Assays Cardiovascular & Metabolic Diseases Central Nervous System & Pain Hit Finding Hit-to-Lead Immunology Infectious Diseases Oncology

VIEW

Dianthus Platform: Screening for Inhibitors of PIK3CA-PIK3R1

Within the PI3K family, the heterodimer comprising the p110-α catalytic and p85-α regulatory subunits (encoded by PIK3CA and PIK3R1) is essential in the regulation of cellular proliferation and carcinogenesis.  To support the discovery of novel PI3K inhibitors, WuXi AppTec offers an integrated platform of ready-to-go assays and Spectral Shift technology within Dianthus, an affinity screening …Read More >

Resource Type: Brochure
Resource Topic: Biophysical Assays Hit Finding Hit-to-Lead Oncology

VIEW

Dianthus Platform: Screening for Inhibitors of PRMT5-WDR77

Protein arginine methyltransferase 5 (PRMT5) is an enzyme which plays an essential role in a wide range of cellular processes.  PRMT5 overexpression has been implicated in many diseases, including cancer, making this protein an important drug target.  To support the discovery of novel PRMT5-WDR77 inhibitors, WuXi AppTec offers an integrated platform of ready-to-go assays and …Read More >

Resource Type: Brochure
Resource Topic: Biophysical Assays Hit Finding Hit-to-Lead Oncology

VIEW

Dianthus Platform: Screening for Modulators of STING

The adaptor protein STING (stimulator of interferon genes) has emerged as an exciting target for both immunological conditions (STING inhibition) and cancer therapies (STING activation).  To support drug discovery teams in the discovery of novel modulators of STING, WuXi AppTec offers an integrated platform of ready-to-go biophysical assays and Dianthus, a plate-based and microfluidics-free affinity …Read More >

Resource Type: Brochure
Resource Topic: Biophysical Assays Hit Finding Hit-to-Lead Immunology Oncology

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!